相似文献
1
Nonalcoholic fatty liver disease.
CMAJ. 2005 Mar 29;172(7):899-905. doi: 10.1503/cmaj.045232.
2
Nonalcoholic fatty liver disease.
Rev Gastroenterol Mex. 2005 Nov;70 Suppl 3:52-6.
3
Nonalcoholic fatty liver disease.
Minerva Med. 2008 Dec;99(6):583-93.
4
Treating nonalcoholic fatty liver disease.
Liver Int. 2007 Nov;27(9):1157-65. doi: 10.1111/j.1478-3231.2007.01567.x.
5
[Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis].
Ned Tijdschr Geneeskd. 2005 Feb 5;149(6):289-94.
6
Nonalcoholic fatty liver disease.
Am Fam Physician. 2006 Jun 1;73(11):1961-8.
7
Recent concepts in non-alcoholic fatty liver disease.
Diabet Med. 2005 Sep;22(9):1129-33. doi: 10.1111/j.1464-5491.2005.01748.x.
8
Hypertension and fatty liver: guilty by association?
J Hum Hypertens. 2007 Apr;21(4):264-70. doi: 10.1038/sj.jhh.1002148. Epub 2007 Feb 1.
9
Nonalcoholic fatty liver disease.
Ann Epidemiol. 2007 Nov;17(11):863-9. doi: 10.1016/j.annepidem.2007.05.013. Epub 2007 Aug 28.
10
Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:31-6. doi: 10.1111/j.1365-2036.2005.02592.x.
引用本文的文献
1
The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Diabetes Metab Syndr Obes. 2025 Jul 23;18:2477-2491. doi: 10.2147/DMSO.S528569. eCollection 2025.
2
Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold.
J Med Chem. 2025 May 8;68(9):9431-9445. doi: 10.1021/acs.jmedchem.4c03132. Epub 2025 Apr 21.
3
Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study.
JCO Clin Cancer Inform. 2025 Feb;9:e2400231. doi: 10.1200/CCI-24-00231. Epub 2025 Feb 14.
4
Polyoxometalates Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease by Activating the AMPK Signaling Pathway.
Int J Nanomedicine. 2024 Oct 25;19:10839-10856. doi: 10.2147/IJN.S485084. eCollection 2024.
5
Effects of Mung Bean Water Supplementation on Modulating Lipid and Glucose Metabolism in a Diabetic Rat Model.
Nutrients. 2024 Aug 13;16(16):2684. doi: 10.3390/nu16162684.
6
Recent advances in liver-on-chips: Design, fabrication, and applications.
Smart Med. 2023 Feb 12;2(1):e20220010. doi: 10.1002/SMMD.20220010. eCollection 2023 Feb.
7
The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment.
Ann Med Surg (Lond). 2024 Jun 20;86(8):4714-4731. doi: 10.1097/MS9.0000000000002276. eCollection 2024 Aug.
8
Characterization of obesity-related diseases and inflammation using single cell immunophenotyping in two different diet-induced obesity models.
Int J Obes (Lond). 2024 Nov;48(11):1568-1576. doi: 10.1038/s41366-024-01584-6. Epub 2024 Jul 14.
9
Biomarkers of Hepatic Toxicity: An Overview.
Curr Ther Res Clin Exp. 2024 Apr 26;100:100737. doi: 10.1016/j.curtheres.2024.100737. eCollection 2024.
10
Trajectory of primordial follicle depletion is accelerated in obese mice in response to 7,12-dimethylbenz[a]anthracene exposure†.
Biol Reprod. 2024 Aug 15;111(2):483-495. doi: 10.1093/biolre/ioae059.
本文引用的文献
1
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.
J Hepatol. 2005 Jan;42(1):132-8. doi: 10.1016/j.jhep.2004.09.012.
2
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.
Am J Gastroenterol. 2004 Dec;99(12):2365-8. doi: 10.1111/j.1572-0241.2004.40064.x.
3
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.
Hepatology. 2004 Dec;40(6):1387-95. doi: 10.1002/hep.20466.
4
Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults.
Arch Intern Med. 2004 Oct 25;164(19):2169-75. doi: 10.1001/archinte.164.19.2169.
5
Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis.
Am J Gastroenterol. 2004 Oct;99(10):1946-52. doi: 10.1111/j.1572-0241.2004.40220.x.
6
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.
Hepatology. 2004 Nov;40(5):1222-5. doi: 10.1002/hep.20420.
7
Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice.
Hepatology. 2004 Aug;40(2):386-93. doi: 10.1002/hep.20302.
8
A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.
Aliment Pharmacol Ther. 2004 Sep 15;20(6):623-8. doi: 10.1111/j.1365-2036.2004.02153.x.
9
Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia.
Indian J Gastroenterol. 2004 Jul-Aug;23(4):131-4.
10
Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease.
Clin Liver Dis. 2004 Aug;8(3):575-94, ix. doi: 10.1016/j.cld.2004.04.006.
Zotero 插件